HALO: Halozyme Therapeutics, Inc.
About
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.
Current Value
$44.571 Year Return
Current Value
$44.571 Year Return
Key Details
Market Cap
$5.70B
P/E Ratio
14.83
1Y Stock Return
15.25%
1Y Revenue Growth
21.35%
Dividend Yield
0.00%
Price to Book
12.6
Strategies that include HALO
Stock's related to HALO
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| PRLB | 40.79% | $907.12M | +1.96% | 0.00% |
| WAT | 40.01% | $20.47B | +25.51% | 0.00% |
| VIR | 39.96% | $954.40M | -26.51% | 0.00% |
| DVAX | 38.22% | $1.58B | -11.37% | 0.00% |
| IDYA | 36.47% | $2.24B | -15.21% | 0.00% |
| ICFI | 34.91% | $2.50B | +3.50% | 0.41% |
| RPRX | 34.89% | $11.56B | -3.67% | 3.22% |
| UTHR | 34.28% | $16.10B | +56.54% | 0.00% |
| CBSH | 33.82% | $9.18B | +51.54% | 1.89% |
| HTBK | 33.63% | $645.52M | +24.17% | 4.92% |
| BEAM | 33.62% | $2.09B | -9.52% | 0.00% |
| UNFI | 33.57% | $1.31B | +44.06% | 0.00% |
| NTB | 33.52% | - | - | 4.69% |
| WRBY | 33.48% | $2.75B | +120.67% | 0.00% |
| SFNC | 33.40% | $3.02B | +48.95% | 3.45% |
| CACI | 33.39% | $9.96B | +37.84% | 0.00% |
| WTFC | 33.31% | $8.72B | +56.17% | 1.38% |
| RHP | 33.26% | $6.69B | +15.31% | 3.95% |
| EGBN | 33.10% | $861.65M | +20.89% | 5.30% |
| MD | 33.10% | $1.25B | +67.55% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| UUU | <0.01% | $4.97M | -41.89% | 0.00% |
| INSM | 0.35% | $13.19B | +202.50% | 0.00% |
| NTZ | -0.37% | $47.64M | -30.94% | 0.00% |
| LUMO | -0.46% | $37.45M | +41.97% | 0.00% |
| NLOP | -0.50% | $458.04M | +94.60% | 0.00% |
| EDSA | -0.50% | $7.11M | -21.79% | 0.00% |
| CVE | 0.52% | $29.32B | -10.19% | 2.95% |
| APEI | -0.72% | $339.36M | +232.64% | 0.00% |
| VTYX | -0.84% | $125.87M | -23.61% | 0.00% |
| GHG | -0.91% | $180.98M | -36.68% | 0.00% |
| GRPN | -0.93% | $353.14M | -10.75% | 0.00% |
| EWTX | -0.93% | $2.98B | +397.00% | 0.00% |
| CATX | -0.94% | $458.24M | +162.59% | 0.00% |
| POAI | -0.99% | $4.29M | -78.60% | 0.00% |
| CRVO | -1.05% | $83.20M | +2.86% | 0.00% |
| HROW | -1.05% | $1.41B | +330.59% | 0.00% |
| STVN | -1.21% | $4.95B | -32.48% | 0.32% |
| NGL | -1.23% | $572.94M | +5.60% | 0.00% |
| BACK | -1.23% | $1.76M | -32.90% | 0.00% |
| PDD | -1.24% | $163.43B | +0.29% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| PULM | -28.50% | $19.83M | +202.98% | 0.00% |
| SRRK | -18.00% | $2.61B | +134.91% | 0.00% |
| NAPA | -17.13% | $1.63B | +9.61% | 0.00% |
| TCTM | -15.20% | $8.10M | -42.99% | 0.00% |
| GAN | -11.28% | $83.39M | +21.19% | 0.00% |
| APD | -11.05% | $72.92B | +18.69% | 2.14% |
| BE | -10.54% | $5.43B | +85.26% | 0.00% |
| ALTM | -9.56% | $5.58B | -23.79% | 0.00% |
| LQDA | -9.34% | $859.91M | +53.94% | 0.00% |
| STG | -9.11% | $35.67M | +7.92% | 0.00% |
| HUSA | -8.77% | $16.69M | -11.56% | 0.00% |
| WPRT | -8.36% | $76.83M | -36.88% | 0.00% |
| PRPO | -8.20% | $9.10M | -13.65% | 0.00% |
| CMP | -8.19% | $608.06M | -42.29% | 2.05% |
| MNR | -8.18% | $1.66B | -10.71% | 15.90% |
| DLNG | -7.97% | $161.93M | +73.23% | 0.00% |
| CMLS | -7.70% | $13.08M | -84.44% | 0.00% |
| CYCN | -7.46% | $4.77M | -16.19% | 0.00% |
| ASR | -6.89% | $7.56B | +26.22% | 0.00% |
| OCFT | -6.64% | $80.95M | -30.38% | 0.00% |
ETF's related to HALO
News
SeekingAlpha
Halozyme's strategic acquisition of Evotec and innovative ENHANZE technology present growth opportunities. Click here for a detailed analysis.
Yahoo
Halozyme Therapeutics (HALO) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Yahoo
HALO vs. FOLD: Which Stock Is the Better Value Option?
Yahoo
Here is how Cencora (COR) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.
Finnhub
-- Halozyme CEO Helen Torley joins to discuss the company's intended acquisition of biotech company Evotech. She speaks with Caroline Hyde on Bloomberg Technology....
Yahoo
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today provided an update on its non-binding proposal to acquire Evotec SE (NASDAQ: EVO) ("Evotec") for €11.00 per share in cash, implying a fully diluted equity value of €2.0 billion. In a presentation posted on its investor relations website, Halozyme highlights how its proposed combination with Evotec would create a leading global innovative pharma services company that would deliver significant value to all stakeholders.
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.